

Filed 26 May 95

Serial No. 08/451,641 (DIV of 08/
245,923)

The invention concerns a series of pteridine deoxyribonucleotide analogs which are highly fluorescent and resemble purine nucleotides in chemical structure and properties. The phosphoramidite form of these fluorophores can be site-specifically incorporated into oligonucleotides using conventional DNA synthesis techniques. The fluorescence intensity of the pteridine nucleotide analogs is highly dependent on their physicochemical environment, thus making them ideal for the study of DNA-protein interactions. A real-time assay for HIV integrase has been developed using one of the pteridine nucleotide analogs that resembles guanosine. Other uses foreseen are as fluorescent labels for DNA probes and PCR primers and for investigating protein-DNA interactions. The claims include the phosphoramidite derivatives of the pteridine nucleotide analogs useful as starting materials for oligonucleotide synthesis and oligonucleotides incorporating the pteridine nucleotide analogs. (portfolio: Gene-Based Therapies—Research Tools and Reagents; Gene-Based Therapies—Diagnostics)

Dated: February 1, 1996.

Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.

[FR Doc. 96-3073 Filed 2-9-96; 8:45 am]

BILLING CODE 4140-01-M

National Heart, Lung, and Blood Institute; Notice of a Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Heart, Lung, and Blood Special Emphasis Panel (SEP) meeting:

Name of SEP: Review of Tuberculosis Academic Award Applications.

Date: March 5, 1996.

Time: 9:00 a.m.

Place: Holiday Inn Chevy Chase, Chevy Chase, Maryland.

Contact Person: Louise P. Corman, Ph.D., Two Rockledge Center, Room 7180, 6701 Rockledge Drive, Bethesda, MD 20892-7924, (301) 435-0270.

Purpose/Agenda: To review and evaluate grant applications.

The meeting will be closed in accordance with the provisions set forth in sec. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information

concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health)

Dated: February 6, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96-3071 Filed 2-9-96; 8:45 am]

BILLING CODE 4140-01-M

National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings:

Name of Committee: National Diabetes and Digestive and Kidney Diseases Special Grants Review Committee, Subcommittee B.

Date: March 7-8, 1996.

Time: 5 p.m.—adjournment on March 8.

Place: Embassy Suites Hotel, 4300 Military Road, NW., Washington, DC 20015.

Contact Person: Ned Feder, Ph.D., Natcher Building, Room 6AS-25S, National Institutes of Health, Bethesda, Maryland 20892-6600, Phone: 301-594-8890.

Purpose/Agenda: To review and evaluate research grant applications.

Name of Committee: National Diabetes and Digestive and Kidney Diseases Special Grants Review Committee, Subcommittee C.

Date: February 29–March 1, 1996.

Time: 8:30 a.m.—adjournment.

Place: Stouffer Mayflower Hotel, 1127 Connecticut Ave., NW., Washington, DC 20036.

Contact Person: Daniel Matsumoto, Ph.D., Natcher Building, Room 6AS-37B, National Institutes of Health, Bethesda, Maryland 20892-6600, Phone: 301-594-8894.

Purpose/Agenda: To review and evaluate research grant applications.

Name of Committee: National Diabetes and Digestive and Kidney Diseases Special Grants Review Committee, Subcommittee D.

Date: March 1, 1996.

Time: 8 a.m.—adjournment.

Place: Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, Maryland 20815.

Contact Person: Ann A. Hagan, Ph.D., Natcher Building, Room 6AS-43G, National Institutes of Health, Bethesda, Maryland 20892-6600, Phone: 301-594-8891.

Purpose/Agenda: To review and evaluate research grant applications.

The meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information

concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program No. 93.847-849, Diabetes, Endocrine and Metabolic Diseases; Digestive Diseases and Nutrition; and Kidney Diseases, Urology and Hematology Research, National Institutes of Health)

Dated: February 6, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96-3072 Filed 2-9-96; 8:45 am]

BILLING CODE 4140-01-M

Prospective Grant of Exclusive License: Cartilage-Derived Morphogenetic Proteins

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license in the United States to practice the invention embodied in U.S. Public Health Service Employee Invention Report Number E-138-94/0 (PCT/US94/12814), entitled "Cartilage-Derived Morphogenetic Proteins" to Creative BioMolecules, Inc., having a place of business in Hopkinton, Massachusetts. The patent rights in this application have been assigned to the United States of America.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The present invention relates generally to the field of cartilage and bone development. More specifically, this invention relates to cartilage-derived morphogenetic proteins (CDMPs) that stimulate development and repair of cartilage *in vivo*. These proteins which exhibit chondrogenic properties are disclosed to be members of the TGF- β superfamily. Also disclosed are polynucleotides encoding two members of the CDMP family of proteins. Recombinant CDMP-1 protein was shown to have chondrogenic activity *in vivo*. The primary uses of this invention would be in orthopaedic reconstruction.

ADDRESSES: Requests for a copy of this patent application, inquires, comments, and other materials relating to the contemplated license should be directed to: John Fahner-Vihtelic, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; Telephone: 301/496-7735 extension 285; Fax: 301/402-0220. A signed Confidentiality Agreement will be required to review copies of the patent application. Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before April 12, 1996 will be considered. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: February 1, 1996.

Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.

[FR Doc. 96-3074 Filed 2-9-96; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[AK-962-1410-00-P; F-21901-05]

Notice for Publication; Alaska Native Claims Selection

In accordance with Departmental regulation 43 CFR 2650.7(d), notice is hereby given that a decision to issue conveyance under the provisions of Sec. 14(e) of the Alaska Native Claims Settlement Act of December 18, 1971, 43 U.S.C. 1601, 1613(e), will be issued to Doyon Limited for approximately 3,794 acres. The lands involved are in the vicinity of Eagle, Alaska, located within T. 2 N., R. 27 E., Fairbanks Meridian, Alaska.

A notice of the decision will be published once a week, for four (4) consecutive weeks, in the Fairbanks Daily News-Miner. Copies of the decision may be obtained by contacting the Alaska State Office of the Bureau of Land Management, 222 West Seventh Avenue, #13, Anchorage, Alaska 99513-7599 (907) 271-5960.

Any party claiming a property interest which is adversely affected by the decision, an agency of the Federal

government or regional corporation, shall have until March 13, 1996 to file an appeal. However, parties receiving service by certified mail shall have 30 days from the date of receipt to file an appeal. Appeals must be filed in the Bureau of Land Management at the address identified above, where the requirements for filing an appeal may be obtained. Parties who do not file an appeal in accordance with the requirements of 43 CFR Part 4, Subpart E, shall be deemed to have waived their rights.

Carolyn A. Bailey,
Land Law Examiner, Branch of Gulf Rim Adjudication.

[FR Doc. 96-3001 Filed 2-9-96; 8:45 am]

BILLING CODE 4310-JA-P

[OR-050-1220-00:G6-0058]

Prineville District; Closure of Public Lands; Oregon

January 31, 1996.

AGENCY: Bureau of Land Management, Interior.

ACTION: Notice is hereby given that the area immediately surrounding Paulina Cave, Crook County, Oregon, is closed to all visitor use.

Paulina Cave in Crook County, Oregon, and the surrounding area extending 150 feet from the rim of the sinkhole, are closed to all visitor use. The purpose of this closure is to protect the western big-eared bat (*Plecotus townsendii*) from human disturbance. This species is extremely sensitive to human disturbance; any disturbance that awakens the bats during hibernation may be sufficient to result in their death. Paulina Cave is a historical hibernaculum for the western big-eared bat. Human disturbance above the cave and surrounding the sinkhole creates significant noise and vibration to disturb roosting western big-eared bats. Human disturbance and visitation at the site would be sufficient to preclude attempts to re-establish use by the western big-eared bat at this site. Exemptions to this closure will apply to administrative personnel for monitoring purposes; other exemptions to this restriction may be made on a case-by-case basis by the authorized officer. Exemptions could include approved research, essential search and rescue, and other emergency actions or administrative operations for cave resources protection. The authority for this closure is 43 CFR 8364.1: Closure and restriction orders.

A more specific location of public lands under this closure order is not

provided in order to protect sensitive cave resources. Cave locations are exempt from the Freedom of Information Act under the Federal Cave Resources Protection Act of 1988.

FOR FURTHER INFORMATION CONTACT: Sarah Nichols, Wildlife Biologist, BLM Prineville District, P.O. Box 550, Prineville Oregon 97754, telephone (541) 416-6700.

SUPPLEMENTARY INFORMATION: Violation of this closure order is punishable by a fine not to exceed \$1,000 and/or imprisonment not to exceed 12 months as provided in 43 CFR 8360.0-7.

Dated: January 31, 1996.

Don Smith,
Acting District Manager, Prineville District Office.

[FR Doc. 96-2954 Filed 2-9-96; 8:45 am]

BILLING CODE 4310-33-M

[D-930-1020-01]

Notice of Intent (NOI) To Modify Land Use Plans (LUPS) and To Prepare an Environmental Impact Statement (EIS) or Other National Environmental Policy Act (NEPA) Documentation To Adopt Standards for Rangeland Health and Guidelines for Grazing Management for BLM Lands in Idaho

AGENCY: Bureau of Land Management, Interior.

ACTION: Revised notice of intent to modify Land Use Plans and to prepare appropriate NEPA documentation to adopt Standards for Rangeland Health and Guidelines for Grazing Management in Idaho.

SUMMARY: The Bureau of Land Management (BLM) in Idaho published an NOI on page 58092 in the issue of Friday, November 24, 1995, to, among other actions, (1) modify all Idaho Management Framework Plans (MFPs) and Resource Management Plans (RMPs) and (2) prepare an EIS to adopt standards for rangeland health and guidelines for grazing management in Idaho. It is now necessary to revise that NOI in order to clarify the preliminary alternatives identified and to extend the public comment period on the NOI and the Planning Criteria which were published in a notice of availability (NOA) on page 65352 in the issue of Friday, December 19, 1995.

DATES: Comments on the NOI of November 24, 1995, on the NOA of December 19, 1995, and this NOI will be accepted for 30 days from the publication date of this NOI.

FOR FURTHER INFORMATION CONTACT: J. David Brunner, Bureau of Land